US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.62

+0.85081.40%

Volume:39.65K

Turnover:2.42M

Market Cap:287.77M

PE:20.16

High:61.62

Open:60.98

Low:60.60

Close:60.77

52wk High:64.10

52wk Low:39.36

Shares:4.67M

Float Shares:4.67M

Volume Ratio:5.09

T/O Rate:0.85%

Dividend:1.53

Dividend Rate:2.48%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Bellevue Flags US Healthcare Innovation as Driving Fresh Investment Opportunities

Long-Term Bribery Involving 30+ Pharmaceutical Firms Prompts Hospital Response

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)

Hospital Staff in Hebei Province Found Guilty of Accepting Bribes 46 Times Over 11 Years, Totaling 184 Million Yuan

MEDCAPTAIN's Hong Kong IPO: A Medical Device Empire Built on Acquisitions Faces Multiple Headwinds

Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares

Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)

Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255

THOMSON REUTERS

BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion

Tellgen's Subsidiary Device Registration Application Accepted by Regulator

LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live

Roivant Sciences Price Target Raised to $46.00/Share from $42.00 by Guggenheim

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Top Midday Gainers

MT Newswires Live

Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/PTH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":61.62,"timestamp":1789401298928,"preClose":60.7692,"halted":0,"volume":39649,"delay":0,"changeRate":0.014000513417981472,"floatShares":4670000,"shares":4670000,"eps":3.057033,"marketStatus":"Trading","change":0.8508,"latestTime":"09-14 11:56:22 EDT","open":60.98,"high":61.62,"low":60.6,"amount":2416045.278756,"amplitude":0.016785,"askPrice":61.63,"askSize":400,"bidPrice":61.52,"bidSize":100,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":60.7692,"sharesOutstanding":2480000,"nav":60.58293,"aum":283728993.67,"dividendRate":0.024753,"bidAskSpread":0.001903,"postHourTrading":{"tag":"盘后","latestPrice":60.85,"preClose":60.7692,"latestTime":"19:30 EDT","volume":14,"amount":850.1752,"timestamp":1789169406061,"change":0.0808,"changeRate":0.00133,"amplitude":0},"volumeRatio":5.085436,"impliedVol":0.1361,"impliedVolPercentile":0.6255},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4670000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":5.085436,"shares":4670000,"dividePrice":1.5253,"high":61.62,"amplitude":0.016785,"preClose":60.7692,"low":60.6,"week52Low":39.36,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":61.62,"committee":-0.6,"eps":3.057033,"divideRate":0.024753,"volume":39649,"delay":0,"ttmEps":3.057033,"open":60.98,"prevYearClose":49.701,"prevWeekClose":60.7692,"prevMonthClose":60.7941,"prevQuarterClose":59.76,"fiveDayClose":61.1284,"twentyDayClose":60.35,"sixtyDayClose":52.7902},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667466962","title":"Bellevue Flags US Healthcare Innovation as Driving Fresh Investment Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667466962?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:11","pubTimestamp":1789391469,"startTime":"0","endTime":"0","summary":"Bellevue flags US healthcare innovation as driving fresh investment opportunitiesBellevue Group AG flagged patient-outcome innovation as a key driver of healthcare investment opportunities from recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL8lm3Sh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","BK4082","BK4139","LU0006061336.USD","LU0648000940.SGD","LU1150488218.USD","BK4588","LU1059921491.USD","LU1894683348.USD","BK4585","LU1854103824.USD","LQDA","LU0130518102.USD","LU0266013472.USD","LU0289961442.SGD","LU0511384066.AUD","BK4007","LU1571399168.USD","LU0162691827.USD","LU0985320562.USD","LU0477156797.USD","LU1894683264.USD","LU0068578508.USD","BDX","LU1489326972.SGD","IHI","LU0433182093.SGD","BK4532","LU1150488135.SGD","LU0289739343.SGD","LU1699723380.USD","LU0072461881.USD","UTHR","ROIV","BK4504","PTH","LU0985489474.SGD","IE00BFXG1179.USD","LU0130103400.USD","LU1201861165.SGD","LU0878866978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122259450","title":"Long-Term Bribery Involving 30+ Pharmaceutical Firms Prompts Hospital Response","url":"https://stock-news.laohu8.com/highlight/detail?id=1122259450","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122259450?lang=en_us&edition=fundamental","pubTime":"2026-09-14 12:21","pubTimestamp":1789359679,"startTime":"0","endTime":"0","summary":"On September 13, China's National Healthcare Security Administration released a report detailing commercial bribery cases in medical institutions' pharmaceutical procurement. The report revealed that...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","RSPH","MEDX","BK1574","BK1100","HART","LNGR","AGNG","BK1583","GDOC","IEIH","LGHT","09996","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668081","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668081?lang=en_us&edition=fundamental","pubTime":"2026-09-14 01:20","pubTimestamp":1789320035,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Cooper Co (COO) with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-cooper-co-coo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-cooper-co-coo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","XLV","COO","BK4588","LABU","GB00BDT5M118.USD","BK4585","BBH","IDNA","XBI","HCSG","RVMD","IE0009354923.USD","IE0009355771.USD","IE00BJT1NW94.SGD","LU1992135472.HKD","BK4198","LU2211815571.USD","PTH","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0002141913.USD","LU0128526141.USD","LU2272731782.SGD","BK4137","IE00BJJMRZ35.SGD","BK4581","CANC","LU2272731600.USD","LU1992135399.USD","BK4139","IE00B4R5TH58.HKD","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173526187","title":"Hospital Staff in Hebei Province Found Guilty of Accepting Bribes 46 Times Over 11 Years, Totaling 184 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1173526187","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173526187?lang=en_us&edition=fundamental","pubTime":"2026-09-13 09:40","pubTimestamp":1789263647,"startTime":"0","endTime":"0","summary":"China's medical insurance regulator, which set up a credit evaluation system for pharmaceutical pricing and procurement in August 2020, has uncovered a significant case of commercial bribery in the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","HART","MDEV","LNGR","BK1583","MEDX","BK1100","AGNG","IEIH","BK1161","BK1574","LGHT","PTH","09939","RSPH","09996","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188732548","title":"MEDCAPTAIN's Hong Kong IPO: A Medical Device Empire Built on Acquisitions Faces Multiple Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=1188732548","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188732548?lang=en_us&edition=fundamental","pubTime":"2026-09-11 15:40","pubTimestamp":1789112453,"startTime":"0","endTime":"0","summary":"MEDCAPTAIN has officially launched its global offering on the Hong Kong stock exchange. Originating from a small infusion equipment manufacturer, the company has leveraged capital support and...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","HART","BK1100","XMMO","09996","BK4585","LNGR","MDEV","AGNG","BK1583","PTH","MYLD","159883","CALF","IEIH","LGHT","RSPH","MEDX","GDOC","02041","KCE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512383","title":"Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512383","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512383?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:01","pubTimestamp":1789088474,"startTime":"0","endTime":"0","summary":"Roivant Sciences director Meghan FitzGerald disposes of USD 798,000 in common sharesRoivant director Meghan FitzGerald exercised stock options for 20,000 common shares at USD 8.8 on Sept. 8.She sold 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL33g4Z7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666516010","title":"Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666516010","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666516010?lang=en_us&edition=fundamental","pubTime":"2026-09-11 05:53","pubTimestamp":1789077203,"startTime":"0","endTime":"0","summary":"Revolution Medicines director Lorence H. Kim disposes of 17,090 common shares worth USD 3.57 millionDirector Lorence H. Kim disclosed sales of 17,090 Revolution Medicines common shares on Sep. 8, 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL1wDHJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE0009354923.USD","RVMD","CANC","IE00BFTCPJ56.SGD","IDNA","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0320765992.SGD","PTH","BBH","IE00B4R5TH58.HKD","BK4139","LU0889565916.HKD","IE0002141913.USD","IE0009355771.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666518829","title":"Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666518829","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666518829?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:40","pubTimestamp":1789065600,"startTime":"0","endTime":"0","summary":"Revolution Medicines barely had time to celebrate the landmark approval of its pancreatic cancer pill before Wall Street demanded to know what's next.Late last month, regulators approved daraxonrasib ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","LU1032466523.USD","LU0109394709.USD","LU1670711040.USD","IE00BFTCPJ56.SGD","LU0985481810.HKD","IE00BSNM7G36.USD","PTH","IE0002141913.USD","IE00BFXG1179.USD","LU2360032135.SGD","IDNA","LU1236620750.USD","LU1983299246.USD","LU1236620834.HKD","LU1868837300.USD","IHE","BK4585","LU0432979614.USD","LU0456855351.SGD","LU0096364046.USD","FTXH","LU1430594728.SGD","IE00BJT1NW94.SGD","LU1585245621.USD","LU0321505439.SGD","LU0882574055.USD","LU1868836757.USD","LU2125154935.USD","LU2133065610.SGD","BK4588","LU0868494617.USD","LU0306806265.USD","BK4534","LU1670710588.SGD","LU1571399168.USD","BBH","IE0009354923.USD","LU1093756168.USD","LU0321505868.SGD","BK4581","LU1868836591.USD","BMY","CANC","RVMD","BK4559","LU0237698245.USD","IE0009355771.USD","LU0114720955.EUR","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666359288","title":"Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666359288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666359288?lang=en_us&edition=fundamental","pubTime":"2026-09-10 23:29","pubTimestamp":1789054182,"startTime":"0","endTime":"0","summary":"Revolution Medicines  could see strong long-term growth from Rasonque sales, expansion into earlier treatment, and new drugs and combination therapies pending upcoming trial results, Morgan Stanley said in a note Thursday.Morgan Stanley models about $12 billion in peak risk-adjusted sales across the company's drug portfolio by 2036, with potential sales of about $18 billion before adjusting for development risks, according to the note.The analysts see Rasonque as the company's main commercial base, while zoldonrasib, elironrasib and earlier-stage drugs could provide additional  sources of growth and reduce reliance on one treatment, while combination treatments could become an important long-term driver by helping the company reach patients earlier in treatment and expand into more cancer types.The next 12 to 18 months will include the US launch of Rasonque, updates in colorectal cancer, progress from early-stage drugs and several late-stage studies, though weaker drug uptake or disapp","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD","CANC","BBH","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","IE00B2B36J28.USD","PTH","IDNA","IE0002141913.USD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE0009354923.USD","BK4139","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666996625","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666996625","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666996625?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047034,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-axsome-therapeutics-axsm-and-ocugen-ocgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-axsome-therapeutics-axsm-and-ocugen-ocgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","PTH","LU2324357040.USD","BK4581","BK4568","BK4139","XBI","LU0029874061.USD","LU0128526141.USD","HCSG","ZYME","AXSM","BK4137","XLV","BK4585","BK4563","OCGN","BK4588","LABU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666640045","title":"Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255","url":"https://stock-news.laohu8.com/highlight/detail?id=2666640045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666640045?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:09","pubTimestamp":1789034986,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4520GO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","CANC","LU0109394709.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","PTH","RVMD","LU0320765992.SGD","IE00B2B36J28.USD","BK4139","IDNA","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BBH","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566940","title":"BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566940","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666566940?lang=en_us&edition=fundamental","pubTime":"2026-09-10 16:32","pubTimestamp":1789029138,"startTime":"0","endTime":"0","summary":"BeOne Medicines FY26 H1 net income climbs to US$464.36 million; revenue rises 32.3% to US$3.22 billionBeOne Medicines posted GAAP net income of US$464.36 million, swinging from profit of US$95.59 mill","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL4kr7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0889565916.HKD","CANC","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BBH","IE0009354923.USD","IDNA","IE0002141913.USD","PTH","BK4139","LU0320765992.SGD","RVMD","IE00B4R5TH58.HKD","IE0009355771.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199145560","title":"Tellgen's Subsidiary Device Registration Application Accepted by Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1199145560","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199145560?lang=en_us&edition=fundamental","pubTime":"2026-09-10 11:54","pubTimestamp":1789012483,"startTime":"0","endTime":"0","summary":"Tellgen Corporation (SZSE: 300642) has announced that its controlling subsidiary, Shanghai Maishi Biotechnology Co., Ltd., recently had its medical device registration application accepted for review...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300642","BK0042","BK0239","BK1100","LNGR","RSPH","MEDX","LGHT","BK1574","159883","PTH","BK0046","09996","IEIH","AGNG","BK1583","GDOC","HART","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156894230","title":"LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1156894230","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156894230?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:08","pubTimestamp":1788998900,"startTime":"0","endTime":"0","summary":"LIFETECH SCI (01302) has announced that it received an official written notice from the National Medical Products Administration (NMPA) on September 9, 2026, confirming that the LantvalTM aortic...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","MDEV","MEDX","PTH","159883","09996","LNGR","BK1583","AGNG","BK1100","01302","HART","GDOC","RSPH","IEIH","BK1600","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666368655","title":"UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666368655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666368655?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960920,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EKG","GDOC","BK4551","BK4196","GH","LU0320765992.SGD","LU0889565916.HKD","BK4585","FFOX","BK4535","HELX","LU0109394709.USD","GNOM","PTH","GNMX","BK4588","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666041535","title":"Roivant Sciences Price Target Raised to $46.00/Share from $42.00 by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2666041535","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666041535?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:30","pubTimestamp":1788960600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666769587","title":"Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666769587","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666769587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952232,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Collegium Pharmaceutical (COLL), Revolution Medicine...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","COLL","BK4556","XLV","IDNA","BK4535","BK4137","IE0002141913.USD","BBH","LU1861558580.USD","LU0889565916.HKD","BK4585","LU0029874061.USD","IE0009354923.USD","IE0009355771.USD","LU0128526141.USD","XBI","IE00BJJMRZ35.SGD","LABU","RVMD","LU1861559042.SGD","IE00B2B36J28.USD","CANC","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4007","BK4139","IE00BJT1NW94.SGD","BK4588","NTLA","LU0320765992.SGD","PTH","LU0109394709.USD","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNTL","IBBQ","BIB","RSPH","JHMH","GNMX","PBPH","IEIH","IBRN","NVIB","APXH","AZNH","LLYX","HYLG","IBB","HRTS","CURE","SURI","CNCR","PJP","BBP","JDOC","PTH","MDTX","IBBJ","FTXH","WDNA","PBE","GSKH","SBIO","FBT","MEDI","BBH","GNOM","LFSC","MRNY","GDOC","FHLC","CANC","PSCH","TBXU","GPCR","SYNB","FXH","IDNA","BME","MEDX","XPH","PINK","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666637458","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666637458","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666637458?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:27","pubTimestamp":1788888467,"startTime":"0","endTime":"0","summary":"Roivant Sciences  shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, met its primary and secondary endpoints.More than 13.5 million shares of the company traded intraday compared with a daily average of about 6.26 million.Intel  is expected to raise personal computer central processing unit prices by another 10% in early October, Digitimes reported, citing supply chain sources.Shares jumped 10%, with intraday trading volume at over 86.0 million, versus the stock's daily average of about 113.4 million.Pharvaris  said that a global phase 3 study of deucrictibant extended-release tablets met the primary endpoint of reducing the mean monthly attack rate by 83%, compared with placebo, in people with hereditary angioedema.Wedbush Securities adjusted Pharvaris' price target to $50 from $42 while maintaining its outperform rating.Shares climbed 10% as int","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2089985449.USD","IE000MB6IJN5.SGD","QQQA","LU2720916845.USD","BK4533","ROIV","AIS","LU2764262908.HKD","BK4543","LU0719512351.SGD","XNTK","LU0742534661.SGD","LU2931357623.SGD","SINTCmain","BK4612","LU0154236417.USD","SOXX","IE000M9KFDE8.USD","LU0251131958.USD","LU0321505868.SGD","DRIV","BK4535","IE000WAW04H5.SGD","LINT","BK4585","AIQ","LU2148611432.USD","LU2360106780.USD","LU0187121727.USD","LU0149725797.USD","BK4527","PTH","TTEQ","BK4588","LU0251142724.SGD","LU0048573561.USD","BK4579","BK4515","BK4534","BK4512","BK4550","BK4605","LU0274383776.USD","BK4602","LU0082616367.USD","LU0081259029.USD","FTXL","BK4529","BK4554","LU1852331112.SGD","BK4007","INYY","LU2250418816.HKD","IE0000B7K699.USD","BK4141","INT","LU0097036916.USD","CHPS","IE000SO60NU8.SGD","BK4575","LU2543165471.USD","LU2244417387.USD","LU0859254822.USD","04335","PHVS","LU2357627491.SGD","LU0321505439.SGD","IE000F7OJYX1.SGD","INTW","LU2764263203.CNY","IE000BZT7R73.USD","HK0000304805.HKD","LEGR","LU0056508442.USD","HK0000304797.USD","BK4139","LU2764263039.SGD","INTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666492371","title":"Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2666492371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666492371?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:35","pubTimestamp":1788885318,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $47 from $41 and keeps a Buy rating on the shares. The firm believes m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-47-from-41-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-47-from-41-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ROIV","PTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}